Vienna, Austria – May 9th 2025 – Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play.

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

IMAGO/Agencia-MexSport Club León's last ditch effort to keep their place in the 2025 FIFA Club World Cup failed, as the Court of Arbitration for Sport (CAS) ruled against the Liga MX club in ...

"Our study is a first step in dramatically expanding our repertoire of effective and safe CRISPR-Cas9 enzymes. In our manuscript, we demonstrate the utility of these PAMmla-predicted enzymes to ...

In May of that year, a team at the University of California, Berkeley, filed its first patent application in the U.S. for CRISPR-Cas9. In December, a different team at the Broad Institute of MIT ...